12 Month Price Forecast For MGTX
Distance to MGTX Price Forecasts
MGTX Price Momentum
๐ค Considering MeiraGTx (MGTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 6:03 PM UTC
MGTX Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, MGTX has a bullish consensus with a median price target of $20.00 (ranging from $11.00 to $36.00). Currently trading at $6.70, the median forecast implies a 198.5% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Daniil Gataulin at Chardan Capital, projecting a 437.3% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 64.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGTX Analyst Consensus
MGTX Price Target Range
Latest MGTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGTX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 18, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
Nov 14, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $11.00 |
Aug 13, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $9.00 |
Jul 31, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
Mar 15, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $11.00 |
Aug 11, 2023 | Chardan Capital | Geulah Livshits | Buy | Reiterates | $41.00 |
Aug 11, 2023 | RBC Capital | Luca Issi | Outperform | Maintains | $11.00 |
May 12, 2023 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $25.00 |
Mar 16, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $41.00 |
Mar 15, 2023 | RBC Capital | Luca Issi | Outperform | Maintains | $22.00 |
Aug 12, 2022 | Chardan Capital | Geulah Livshits | Buy | Maintains | $47.00 |
May 13, 2022 | Chardan Capital | Geulah Livshits | Buy | Maintains | $46.00 |
May 13, 2022 | Barclays | Gena Wang | Overweight | Maintains | $18.00 |
Oct 23, 2020 | RBC Capital | Outperform | Initiates | $0.00 | |
Sep 3, 2019 | Piper Sandler | Overweight | Initiates | $0.00 | |
Sep 3, 2019 | Piper Jaffray | Overweight | Initiates | $0.00 | |
Jul 9, 2018 | Evercore ISI Group | Outperform | Initiates | $0.00 | |
Jul 3, 2018 | Barclays | Overweight | Initiates | $0.00 |
Stocks Similar to MeiraGTx Holdings plc
The following stocks are similar to MeiraGTx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

MeiraGTx Holdings plc (MGTX) Financial Data
MeiraGTx Holdings plc has a market capitalization of $523.63M with a P/E ratio of -4.5x. The company generates $13.93M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +113.8% quarter-over-quarter, while maintaining an operating margin of -367.0% and return on equity of -94.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

MeiraGTx Holdings plc (MGTX) Company Overview
About MeiraGTx Holdings plc
Develops gene therapies for serious diseases.
MeiraGTx Holdings operates as a clinical-stage gene therapy company, focusing on developing innovative treatments for serious diseases, particularly ocular and neurodegenerative diseases. The company generates revenue through collaborations, such as its partnership with Janssen Pharmaceuticals, and through the advancement of its clinical programs, which may lead to eventual product commercialization.
Founded in 2015 and headquartered in New York, MeiraGTx is involved in multiple clinical trials, including therapies for achromatopsia and Parkinson's disease. Its focus on rare genetic disorders positions it in a niche but potentially lucrative market, appealing to investors interested in biotech innovations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
387
CEO
Dr. Alexandria Forbes Ph.D.
Country
United States
IPO Year
2018
Website
meiragtx.comMeiraGTx Holdings plc (MGTX) Latest News & Analysis
MeiraGTx has obtained Rare Pediatric Disease Designation for four inherited retinal diseases, highlighting its proprietary technology's therapeutic potential.
MeiraGTx's RPDD for four IRDs enhances its market positioning, potentially attracting investment and partnerships, and may lead to expedited development and commercialization of their therapies.
MeiraGTx Holdings plans a near-term BLA filing for AAV-AIPL1 in the UK for Leber congenital amaurosis 4 and anticipates a 2025 filing for Bota-vec for X-linked Retinitis Pigmentosa. Phase 3 study for AAV-GAD in Parkinson's is set for 2025.
MeiraGTx's advancements in gene therapies and upcoming BLA filings signal potential revenue growth and market expansion, impacting stock performance and investor sentiment.
MeiraGTx Holdings: Behind The Recent Rally
2 months agoMeiraGTx Holdings plc's stock rose over 40% after positive Parkinson's disease data. The company has a diverse gene therapy pipeline and expects multiple BLAs from 2024-2027, supported by deals with J&J and Sanofi.
MeiraGTx's 40% rally reflects strong investor confidence driven by positive Parkinson's data, strategic partnerships, and a promising pipeline, indicating potential for significant future returns.
MeiraGTx Holdings PLC (MGTX) reported a quarterly loss of $0.54 per share, worse than the expected loss of $0.47, improving from a loss of $0.74 per share a year prior.
MeiraGTx's larger-than-expected quarterly loss may signal ongoing financial challenges, impacting investor confidence and stock performance amid year-over-year improvement.
MeiraGTx (MGTX) experienced significant trading volume recently, but recent earnings estimate revisions may hinder its upward momentum in the near term.
Higher trading volume in MeiraGTx signals increased interest, but negative earnings estimate revisions could indicate potential declines, affecting investor sentiment and stock performance.
MeiraGTx stock increased by 15% after its gene therapy candidate showed superior results compared to a sham treatment in patients with Parkinson's disease.
MeiraGTx's stock surge indicates strong investor confidence in its gene therapy's efficacy, potentially leading to increased market share and future revenue in the Parkinson's treatment sector.
Frequently Asked Questions About MGTX Stock
What is MeiraGTx Holdings plc's (MGTX) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, MeiraGTx Holdings plc (MGTX) has a median price target of $20.00. The highest price target is $36.00 and the lowest is $11.00.
Is MGTX stock a good investment in 2025?
According to current analyst ratings, MGTX has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MGTX stock?
Wall Street analysts predict MGTX stock could reach $20.00 in the next 12 months. This represents a 198.5% increase from the current price of $6.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MeiraGTx Holdings plc's business model?
MeiraGTx Holdings operates as a clinical-stage gene therapy company, focusing on developing innovative treatments for serious diseases, particularly ocular and neurodegenerative diseases. The company generates revenue through collaborations, such as its partnership with Janssen Pharmaceuticals, and through the advancement of its clinical programs, which may lead to eventual product commercialization.
What is the highest forecasted price for MGTX MeiraGTx Holdings plc?
The highest price target for MGTX is $36.00 from Daniil Gataulin at Chardan Capital, which represents a 437.3% increase from the current price of $6.70.
What is the lowest forecasted price for MGTX MeiraGTx Holdings plc?
The lowest price target for MGTX is $11.00 from Luca Issi at RBC Capital, which represents a 64.2% increase from the current price of $6.70.
What is the overall MGTX consensus from analysts for MeiraGTx Holdings plc?
The overall analyst consensus for MGTX is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are MGTX stock price projections?
Stock price projections, including those for MeiraGTx Holdings plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.